Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer
- Athenex Inc (NASDAQ: ATNX) announced a clinical trial collaboration and supply agreement with Merck Co & Inc (NYSE: MRK).
- The agreement applies to the expansion phase of the Phase 1 clinical trial evaluating Athenex's oral paclitaxel combined with Merck's Keytruda (pembrolizumab) for certain NSCLC patients.
- The agreement will support the trial's expansion phase to investigate further the preliminary results of the KX-ORAX-011 Phase 1 trial evaluating Oraxol (encequidar plus oral paclitaxel) in combination with pembrolizumab for certain NSCLC patients.
- The two companies will form a Joint Development Committee to review the clinical trial results.
- The NSCLC expansion cohort is actively recruiting and aims to enroll approximately 50 patients.
- Price Action: ATNX shares are up 2.15% at $0.48 during the market session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech Large Cap News Penny Stocks Health Care Contracts General
